Sidney Kimmel Comprehensive Cancer Center At Thomas Jefferson University

This early-phase study tests the safety of combining two types of radiation therapy for men with intermediate-risk prostate cancer. Participants receive a short internal radiation treatment followed by three weeks of highly targeted external radiation. The goal is to see if this …

This study was designed to find a safe dose of the drug Torisel when added to standard chemotherapy and radiation for people with advanced head and neck cancer. The goal was to see if the combination could be given safely and help prevent the cancer from coming back. However, the…

This study tests two drugs, sunitinib and valproic acid, to see if they can prevent high-risk uveal melanoma (a type of eye cancer) from spreading to other parts of the body. About 210 people who have already had their eye tumor treated are taking one of these drugs for up to a y…

This study tests a precise radiation therapy that targets brain tumors while sparing the scalp to reduce wound infections and other side effects. About 100 adults with newly diagnosed grade II to IV gliomas will receive this treatment. The goal is to see if this approach is safer…

This study tests whether linaclotide, a drug that helps the intestines release water and salt, can slow or prevent colorectal cancer. About 230 people with colorectal adenomas (precancerous growths) or early-stage colorectal cancer will take the drug or a placebo before surgery. …

This study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goa…

This study was planned to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. It was a phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…